Trial · NCT03181893
Participant flow66
How many started, completed or left each group, period by period.
1 to 20 of 66
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Baseline to Week 12 (All Stages) | STARTED | (Stage 1) Placebo | 10 | |
| Baseline to Week 12 (All Stages) | STARTED | (Stage 1) PF-06823859 600 mg Intravenous (IV) | 22 | |
| Baseline to Week 12 (All Stages) | STARTED | (Stage 2) Placebo | 1 | |
| Baseline to Week 12 (All Stages) | STARTED | (Stage 2) PF-06823859 150 mg IV | 5 | |
| Baseline to Week 12 (All Stages) | STARTED | (Stage 2) PF-06823859 600 mg IV | 3 | |
| Baseline to Week 12 (All Stages) | STARTED | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | 2 | |
| Baseline to Week 12 (All Stages) | STARTED | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | 1 | |
| Baseline to Week 12 (All Stages) | STARTED | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | 10 | |
| Baseline to Week 12 (All Stages) | STARTED | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | 3 | |
| Baseline to Week 12 (All Stages) | STARTED | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | 9 | |
| Baseline to Week 12 (All Stages) | STARTED | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | 9 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Stage 1) Placebo | 9 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Stage 1) PF-06823859 600 mg Intravenous (IV) | 20 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Stage 2) Placebo | 1 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Stage 2) PF-06823859 150 mg IV | 5 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Stage 2) PF-06823859 600 mg IV | 3 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | 2 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | 1 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | 10 | |
| Baseline to Week 12 (All Stages) | COMPLETED | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181893/flow